We set out to answer these questions by using two widely studied murine NSCLC models, namely those driven by the KrasG12D (Kras) oncogene, concomitantly with loss of either the tumour suppressor gene Trp53 (p53) 12 or the serine/threonine kinase 11 gene (Stk11, also known as Lkb1) 13, 14, 15, 16. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.